SCHEMBL7956096

SCHEMBL7956096

COc1ccc(S(=O)(=O)OC(=O)C2CCN(Cc3ccc(C)cc3)CC2)cc1

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.55
MMP9 P14780 2/20 0.55
MMP13 P45452 2/20 0.55
ADAM17 P78536 2/20 0.55
MCHR1 Q99705 1/20 0.52
HRH3 Q9Y5N1 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 3/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 1/20 0.49
PKM P14618 1/20 0.49
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SIGMAR1 Q99720 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6567555 0.96 MEN1 (0.54) MMP1MMP9MMP13ADAM17MEN1
SCHEMBL7345881 0.88 S1PR5 (0.60) MMP1MMP9MMP13ADAM17HRH3
SCHEMBL7355241 0.85 KDM4E (0.67) MMP1MMP9MMP13ADAM17MEN1
SCHEMBL7509075 0.83 MMP1 (0.61) MMP1MMP9MMP13ADAM17MEN1
SCHEMBL7347681 0.81 ALDH1A1 (0.64) HRH3MEN1KMT2AKDM4EALDH1A1
SCHEMBL7506962 0.80 MMP1 (0.54) MMP1MMP9MMP13ADAM17ALDH1A1
SCHEMBL493434 0.80 MEN1 (0.61) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL7998480 0.80 OPRM1 (0.55) MMP1MMP9MMP13ADAM17MEN1
SCHEMBL6988354 0.79 KDM4E (0.74) HRH3MEN1KMT2AKDM4EALDH1A1
SCHEMBL7353607 0.78 S1PR5 (0.58) MMP1MMP9MMP13ADAM17HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331563-B1 LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE WYETH HOLDINGS CORPORATION 2001-12-18 US disclosed